Skip to content
lifestyle.chroniccities.us
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Satellos Bioscience Inc.
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
July 8, 2026
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
June 29, 2026
Satellos to Present Clinical Program Updates at ICNMD 2026
June 25, 2026
Satellos Bioscience Announces Results of Annual Meeting of Shareholders
June 17, 2026
Satellos to Participate in Upcoming Investor Conferences
May 27, 2026
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
May 15, 2026
Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
April 9, 2026
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
March 27, 2026
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference
March 10, 2026